Synergistic inhibitory activities of interleukin-10 and dexamethasone on human CD4+ T cells.

Background. We have previously demonstrated that interleukin (IL)-10 synergizes with dexamethasone (Dex) in inhibiting proliferation of human T cells, stimulated in an antigen-presenting cell (APC)-dependent manner. Because IL-10 effectively inhibits APC accessory functions, the synergism could have been a result of its effect on APC. We then investigated the effects of Dex and IL-10 on T-cell subpopulations, stimulated in an APC-independent manner. Methods. CD4 + and CD8 + T cells were stimulated with anti-CD3, with or without Dex and IL-10, alone or in combination. Proliferation, glucocorticoid (GC) receptor binding, anti-CD3-induced tyrosine phosphorylation, IL-2 production, and expression of IL-2 receptor α, β, and γ chains were evaluated. The pharmacologic interactions were analyzed using the isobole method. Results. IL-10 synergized with Dex in inhibiting CD4 + but not CD8 + T-cell proliferation. The synergism was not associated with modifications of GC receptor number or affinity, nor with modifications of anti-CD3-induced tyrosine phosphorylation. IL-10 synergized with Dex in inhibiting IL-2 production and increased Dex inhibitory effect on the expression of the IL-2 receptor a chain, which is up-regulated by CD3 stimulation and IL-2. Only Dex inhibited the β and γ chain expression, which, interestingly, is not up-regulated by IL-2. IL-2, as well as IL-7 and IL-15, reversed the effects of IL-10 but not those of Dex. Conclusions. IL-10 synergizes with Dex in inhibiting CD4 + T-cell proliferation. Its synergizing effect is mediated by the inhibition of IL-2 production. Dex exerts additional activities, such as the inhibition of β and γ chain expression. Therefore, IL-10 could be useful for the enhancement of GC-based immunosuppressive therapies.